Background

The incorporation of fluorine has been instrumental in the discovery and development of novel medicines in a number of therapeutic areas. Approximately 25 percent of all marketed drugs contain fluorine, including six of the 20 best-selling drugs in 2012. Today, SciFluor is positioned to harness the power of fluorine to add value across the entire drug development process and, ultimately, to deliver more innovative treatments to patients.

Why Fluorine?


SciFluor scientists have applied specialized expertise to create a portfolio of fluorine-enabled small molecule therapeutics and a range of capabilities that are unique in the biopharmaceutical industry. SciFluor-discovered, proprietary, fluorine-enhanced new chemical entities (NCEs) are based on known compounds directed toward precedented biological targets. These NCEs represent "de-risked" development candidates that have been tested preclinically and are ready to enter partner development pipelines.



SciFluor News

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
read more >

SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
read more >

SciFluor Life Sciences Awarded Second U.S. Patent for Integrin αvβ3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
read more >

SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
read more >

SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
read more >

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders
read more >